| 9.58 Data as of May 24 |  -0.38 / -3.82%Today’s Change | 7.21 Today|||52-Week Range 12.77 | -1.14% Year-to-Date |
| Previous close | 9.96 |
| Today’s open | 9.87 |
| Day’s range | 9.53 - 9.87 |
| Volume | 826,352 |
| Average volume (3 months) | 1,285,672 |
| Market cap | $781.9M |
| Dividend yield | -- |
| Earnings growth (last year) | +10.85% |
| Earnings growth (this year) | -20.75% |
| Earnings growth (next 5 years) | +60.00% |
| Revenue growth (last year) | +2.12% |
| P/E ratio | NM |
| Price/Sales | 24.13 |
| Price/Book | 9.54 |
| Today’s change | Today’s % change | |
|---|---|---|
| HALOHalozyme Therapeutic... | -0.03 | -0.40% |
| MNTAMomenta Pharmaceutic... | +0.08 | +0.60% |
| SZYMSolazyme Inc | +0.44 | +4.11% |
| PLXProtalix Biotherapeu... | 0.00 | 0.00% |
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.70 |
| Annual revenue (last year) | $26.2M |
| Annual profit (last year) | -$150.1M |
| Net profit margin | -705.62% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Daniel G. Welch, MBA |
Executive VP, Chief Financial & Accounting Officer John C. Hodgman, MBA |
Corporate headquarters Brisbane, California |
.
